IP Group — Pfizer-Metsera deal offers upside potential
There have been several announcements on technical and commercial progress across IP Group’s portfolio this year. A recent highlight was Pfizer’s...
395 Views
IP Group — Exit target of over £250m by end-FY27 reiterated
IP Group continues to deliver a meaningful level of realisations with £30.3m in proceeds generated in H125, more than two-thirds of which came from...
251 Views
NOBA Bank: Flash Note on Valuation Ahead of Stockholm IPO
The article highlights the attractive entry point of SEK70/share for the IPO, with potential for significant upside in the near term and beyond.
416 Views
IP Group — Roadmap to value
IP Group made good progress in crystallising its portfolio values through exits, with proceeds of £183m collected in FY24, most notably from the...
317 Views
IP Group — Examining Istesso’s Phase IIb trial results
Istesso, IP Group’s largest private life sciences holding (c 11% of end-June 2024 portfolio value), has announced the results of its Phase IIb...
190 Views